Skip to main content
European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS
Contenuto archiviato il 2024-05-29

Pre-clinical evaluation of stem cell therapy in stroke

Obiettivo

Using stem cells (SC) multipotent properties has become a challenging research field for most clinical areas, especially in disciplines lacking treatment options such as brain disorders and lesions. In particular, stroke or ischemic cerebrovascular disease accounts for roughly half of the patients hospitalised for neurological diseases and is associated with a large proportion of the health care costs in Europe. Until now, all neuroprotective approaches having yielded positive results in animal models have proven ineffective in clinical trials.
SC clonal populations expected capacity to self-renew and differentiate efficiently into the desired cell type promise to produce beneficial effects in many diseases. Several studies indicate the therapeutic potential of SC in stroke after transplantation of various SC types.
However, standardisation of ditions to regulate SC proliferation and differentiation to produce the «ideal» graft need to be better defined; changes induced by their transplantation into lesioned brain structures are unknown, as is the full extent of functional improvement at long-term post-stroke delays. STEMS deals with the therapeutic aim of using SC to reduce stroke-induced brain dysfunctions. Its main objective is to determine the extent and limits of SC therapy in stroke to pave the way for clinical trials. It will be achieved through the completion of six successive and complementary goals:
- Definition of standard experimental ditions for proliferation, guided differentiation and mass-production
- Identification of the best transplantation protocol regarding post-stroke delays in a rat model of focal ischemia
- trol of safety and compatibility aspects
- Quantification of the effects of SC transplantation on functional impairments
- Transposition of the optimal experimental ditions to non-human primates
- Definition of the relevant human cell therapy product and operating procedures to be applied to stroke patient

Invito a presentare proposte

FP6-2005-LIFESCIHEALTH-6
Vedi altri progetti per questo bando

Coordinatore

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MÉDICALE
Contributo UE
Nessun dato
Costo totale
Nessun dato

Partecipanti (8)